Glycomine, Inc. is a clinical-stage biotechnology company headquartered in San Carlos, California, that specializes in developing therapeutics for serious rare genetic diseases which currently lack disease-modifying treatment options. Founded in 2014, the company is focused on creating replacement therapies that restore missing biological functions in patients suffering from these rare disorders.

The company’s lead product candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a life-threatening rare genetic disease characterized by defective glycosylation. Unlike symptom-only therapies, GLM101 aims to be disease-modifying and is currently undergoing clinical trials including Phase 2b.

Glycomine’s mission is to develop therapeutics for the approximately 7,000 rare disorders worldwide, addressing the unmet medical needs of more than 20 million people affected by rare diseases in the U.S. alone. The company has successfully raised substantial funding, including a $115 million Series C round in April 2025, aimed at advancing its lead program deeper into clinical development.

The company also holds several patents related to rare diseases, autosomal recessive disorders, and protein therapeutics, underscoring its commitment to pioneering treatments in this specialized biotech field. Its approach includes substrate, enzyme, and protein replacement therapies to restore biological functions lost due to rare genetic defects.

With robust financial backing from notable investors like CTI Life Sciences Fund, abrdn Inc., Advent Life Sciences, Novo Holdings, and Sanofi Ventures, Glycomine is well-positioned to advance its therapies and improve patient outcomes for rare genetic disorders.